Mapping Disorders with Neurological Features Through Mitochondrial Impairment Pathways: Insights from Genetic Evidence
Open Access
- 1 July 2025
- journal article
- review article
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 47 (7) , 504
Abstract
Mitochondrial dysfunction is a key driver of neurological disorders due to the brain’s high energy demands and reliance on mitochondrial homeostasis. Despite advances in genetic characterization, the heterogeneity of mitochondrial diseases complicates diagnosis and treatment. Mitochondrial dysfunction spans a broad clinical spectrum, from early-onset encephalopathies to adult neurodegeneration, with phenotypic and genetic variability necessitating integrated models of mitochondrial neuropathology. Mutations in nuclear or mitochondrial DNA disrupt energy production, induce oxidative stress, impair mitophagy and biogenesis, and lead to neuronal degeneration and apoptosis. This narrative review provides a structured synthesis of current knowledge by classifying mitochondrial-related neurological disorders according to disrupted biochemical pathways, in order to clarify links between genetic mutations, metabolic impairments, and clinical phenotypes. More specifically, a pathway-oriented framework was adopted that organizes disorders based on the primary mitochondrial processes affected: oxidative phosphorylation (OXPHOS), pyruvate metabolism, fatty acid β-oxidation, amino acid metabolism, phospholipid remodeling, multi-system interactions, and neurodegeneration with brain iron accumulation. Genetic, clinical and molecular data were analyzed to elucidate shared and distinct pathophysiological features. A comprehensive table synthesizes genetic causes, inheritance patterns, and neurological manifestations across disorders. This approach offers a conceptual framework that connects molecular findings to clinical practice, supporting more precise diagnostic strategies and the development of targeted therapies. Advances in whole-exome sequencing, pharmacogenomic profiling, mitochondrial gene editing, metabolic reprogramming, and replacement therapy—promise individualized therapeutic approaches, although hurdles including heteroplasmy, tissue specificity, and delivery challenges must be overcome. Ongoing molecular research is essential for translating these advances into improved patient care and quality of life.Keywords
This publication has 83 references indexed in Scilit:
- Mitochondria and its epigenetic dynamics: Insight into synaptic regulation and synaptopathiesFunctional & Integrative Genomics, 2025
- Cellular and Molecular Responses to Mitochondrial DNA Deletions in Kearns-Sayre Syndrome: Some Underlying MechanismsMolecular Neurobiology, 2024
- Kufor Rakeb Syndrome with Novel Mutation and the Role of Deep Brain StimulationMovement Disorders Clinical Practice, 2022
- Maternal ornithine transcarbamylase deficiency, a genetic condition associated with high maternal and neonatal mortality every clinician should know: A systematic reviewAmerican Journal of Medical Genetics Part A, 2019
- Recurrent rhabdomyolysis and glutaric aciduria type I: a case report and literature reviewWorld Journal of Pediatrics, 2016
- Leigh syndrome: One disorder, more than 75 monogenic causesAnnals of Neurology, 2015
- Biochemical abnormalities in Pearson syndromeAmerican Journal of Medical Genetics Part A, 2015
- Lack of the Mitochondrial Protein Acylglycerol Kinase Causes Sengers SyndromeThe American Journal of Human Genetics, 2012
- Rett syndrome: Revised diagnostic criteria and nomenclatureAnnals of Neurology, 2010
- Neuroferritinopathy: A Window on the Role of Iron in NeurodegenerationBlood Cells, Molecules, and Diseases, 2002